Ruggeri, M <br/><br/>
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.  [electronic resource] 

 -  Expert review of pharmacoeconomics & outcomes research  Jun 2019 
 - 363-374 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1744-8379 
<br/><br/><label>Standard No.: </label>10.1080/14737167.2019.1537784  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--administration & dosage<br/>Benzimidazoles--administration & dosage<br/>Carbamates<br/>Cohort Studies<br/>Cost-Benefit Analysis<br/>Drug Therapy, Combination<br/>Fluorenes--administration & dosage<br/>Genotype<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Italy<br/>Markov Chains<br/>Pyrrolidines<br/>Quality-Adjusted Life Years<br/>Ribavirin--administration & dosage<br/>Simeprevir--administration & dosage<br/>Sofosbuvir--administration & dosage<br/>Uridine Monophosphate--administration & dosage<br/>Valine--analogs & derivatives